Foghorn Therapeutics (FHTX) Free Cash Flow (2019 - 2026)

Foghorn Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$25.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 5.44% year-over-year to -$25.3 million; the TTM figure through Mar 2026 stood at -$87.5 million (up 8.77% YoY), while the FY2025 annual figure was -$86.1 million, up 14.97% from the prior year.
• Free Cash Flow was -$25.3 million for Q1 2026 at Foghorn Therapeutics, down from -$22.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $271.3 million in Q1 2022 to a low of -$32.0 million in Q2 2023.
• Historically, Free Cash Flow has averaged -$8.1 million across 5 years, with a median of -$25.3 million in 2026.
• Biggest YoY gain for Free Cash Flow was 1187.72% in 2022; the steepest drop was 347.36% in 2022.
• A 5-year view of Free Cash Flow shows it stood at -$29.2 million in 2022, then climbed by 9.61% to -$26.4 million in 2023, then climbed by 4.75% to -$25.1 million in 2024, then increased by 11.2% to -$22.3 million in 2025, then decreased by 13.35% to -$25.3 million in 2026.
• The last three Free Cash Flow figures came in at -$25.3 million (Q1 2026), -$22.3 million (Q4 2025), and -$18.8 million (Q3 2025), per Business Quant data.